Dose Range Study of CD5789 in Acne Vulgaris
Recruiting in Palo Alto (17 mi)
+23 other locations
Age: < 65
Sex: Any
Travel: May Be Covered
Time Reimbursement: Varies
Trial Phase: Phase 2
Waitlist Available
Sponsor: Galderma R&D
Prior Safety Data
Trial Summary
What is the purpose of this trial?
To assess the efficacy and safety of different concentrations of CD5789 cream in participants with acne vulgaris for the purpose of dose identification.
Research Team
MG
Michael Graeber, M.D.
Principal Investigator
Galderma R&D, Inc.
Eligibility Criteria
Inclusion Criteria
Stratum 1: IGA score of 3 or 4
Stratum 2: IGA score of 4
Stratum 3: IGA score of 3 or 4
See 4 more
Treatment Details
Interventions
- CD5789 (Other)
Participant Groups
5Treatment groups
Experimental Treatment
Active Control
Placebo Group
Group I: Vehicle CreamExperimental Treatment1 Intervention
Participants randomized in stratum 1, 2 and 3 were applied with Vehicle Cream once daily for 12 weeks.
Group II: CD5789 50 mcg/g CreamExperimental Treatment1 Intervention
Participants randomized in stratum 1, 2 and 3 were applied with 50 mcg/g CD5789 50 once daily for 12 weeks.
Group III: CD5789 25 mcg/g CreamExperimental Treatment1 Intervention
Participants randomized in stratum 1, 2 and 3 were applied with 25 mcg/g CD5789 cream, once daily for 12 weeks.
Group IV: CD5789 100 mcg/g CreamActive Control1 Intervention
Participants randomized in stratum 1, 2 and 3 were applied with 100 mcg/g CD5789 cream, once daily for 12 weeks.
Group V: Tazarotene 0.1% GelPlacebo Group1 Intervention
Participants randomized in stratum 1 and 2 were applied with Tazarotene 0.1% Gel, once daily for 12 weeks.
Find a Clinic Near You
Who Is Running the Clinical Trial?
Galderma R&D
Lead Sponsor
Trials
303
Recruited
60,700+
Flemming Ørnskov
Galderma R&D
Chief Executive Officer since 2019
MD, MPH
Baldo Scassellati Sforzolini
Galderma R&D
Chief Medical Officer
MD, PhD